Indian and German firms sign NDA to co‑produce immunoglobulin medicines

Indian biotech VINS Bioproducts Ltd and Germany's Neovii Biotech GmbH have signed a non‑disclosure agreement to work together on manufacturing and commercialising immunoglobulin products, including anti‑thymocyte globulin used in organ transplants. The Indian Embassy in Berlin arranged the NDA exchange on the sidelines of the Indo‑German Health Leadership Dialogue on 13 October 2026. The deal covers technology transfer to India, allowing local production of the specialised biologics. Anti‑thymocyte globulin treats patients undergoing organ transplantation and certain blood disorders, and currently many such drugs are imported into India. By building domestic capacity, the partnership could improve access to these medicines and cut reliance on overseas supplies. The collaboration aims to set up manufacturing lines, train Indian staff in the German technology and eventually launch the products in the Indian market.

Context

India imports a large share of immunoglobulin therapies, which are critical for transplant patients and some hematological conditions. Local production through technology transfer can lower costs, shorten supply chains and enhance self‑reliance in a high‑need medical segment.